

Dominic Mitchell

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4742459/publications.pdf>

Version: 2024-02-01

12
papers

98
citations

1306789

7
h-index

1372195

10
g-index

12
all docs

12
docs citations

12
times ranked

160
citing authors

#	ARTICLE	IF	CITATIONS
1	Cost-effectiveness of direct-acting antiviral regimen ombitasvir/paritaprevir/ritonavir in treatment-naïve and treatment-experienced patients infected with chronic hepatitis C virus genotype 1b in Japan. <i>Journal of Medical Economics</i> , 2016, 19, 1144-1156.	1.0	19
2	Economic Evaluation of a Pharmacogenomics Test for Statin-Induced Myopathy in Cardiovascular High-Risk Patients Initiating a Statin. <i>Molecular Diagnosis and Therapy</i> , 2017, 21, 95-105.	1.6	16
3	Impact of mineral and bone disorder on healthcare resource use and associated costs in the European Fresenius medical care dialysis population: a retrospective cohort study. <i>BMC Nephrology</i> , 2012, 13, 140.	0.8	12
4	A Discrete Event Simulation Model to Assess the Economic Value of a Hypothetical Pharmacogenomics Test for Statin-Induced Myopathy in Patients Initiating a Statin in Secondary Cardiovascular Prevention. <i>Molecular Diagnosis and Therapy</i> , 2018, 22, 241-254.	1.6	12
5	Cost-effectiveness of elagolix versus leuprolide acetate for treating moderate-to-severe endometriosis pain in the USA. <i>Journal of Comparative Effectiveness Research</i> , 2019, 8, 337-355.	0.6	12
6	Burden of illness of bone metastases in prostate cancer patients in Québec, Canada: A population-based analysis. <i>Canadian Urological Association Journal</i> , 2015, 9, 307.	0.3	12
7	A Cost-Effectiveness Analysis of Glecaprevir/Pibrentasvir Versus Existing Direct-Acting Antivirals to Treat Chronic Hepatitis C in Japan. <i>Advances in Therapy</i> , 2020, 37, 457-476.	1.3	8
8	Bias within economic evaluations – the impact of considering the future entry of lower-cost generics on currently estimated incremental cost-effectiveness ratios of a new drug. <i>ClinicoEconomics and Outcomes Research</i> , 2015, 7, 497.	0.7	4
9	A model to assess the cost-effectiveness of pharmacogenomics tests in chronic heart failure: the case of ivabradine. <i>Pharmacogenomics</i> , 2016, 17, 1693-1706.	0.6	1
10	Value of a Hypothetical Pharmacogenomic Test for the Diagnosis of Statin-Induced Myopathy in Patients at High Cardiovascular Risk. <i>Molecular Diagnosis and Therapy</i> , 2018, 22, 641-652.	1.6	1
11	Cost-effectiveness model for a hypothetical monotherapy vs standard of care in adult patients with treatment-resistant depression. <i>ClinicoEconomics and Outcomes Research</i> , 2019, Volume 11, 257-270.	0.7	1
12	Maximal expected benefits from lowering cholesterol in primary prevention for a high-risk population. <i>Current Medical Research and Opinion</i> , 2016, 32, 1955-1958.	0.9	0